Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nykode Therapeutics

Less than 1K followers

NYKD

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor views

Nykode Therapeutics is a biotechnology company. The company specializes in the research and development of immunological therapies and vaccines. The solutions are mainly used for the treatment of patients with cancer and other serious health conditions that require long-term treatment. The largest operations are in the European market.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
25.11.
2026

Interim report Q3'26

24.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Regulatory press release09.09.2026 klo 15.59

NYKD: Nykode Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Nykode Therapeutics
Regulatory press release31.08.2026 klo 16.26

Nykode Therapeutics ASA - New share capital registered

Nykode Therapeutics
Regulatory press release31.08.2026 klo 12.35

NYKD: Mandatory notification of transaction

Nykode Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release28.08.2026 klo 01.20

NYKD: Mandatory notification of trade

Nykode Therapeutics
Regulatory press release28.08.2026 klo 00.51

Nykode Therapeutics ASA - Private Placement Completed

Nykode Therapeutics
Regulatory press release27.08.2026 klo 17.32

Nykode Therapeutics ASA - Contemplated Private Placement

Nykode Therapeutics
Regulatory press release26.08.2026 klo 16.15

NYKD: Nykode Therapeutics receives draft recommendation from Secretariat of Tax Appeal Board in pending tax case

Nykode Therapeutics
Regulatory press release26.08.2026 klo 08.00

Nykode Therapeutics - Quarterly Report Q2 2026

Nykode Therapeutics
Regulatory press release21.08.2026 klo 20.19

Nykode Therapeutics - Invitation to Q2 2026 Financial Results Presentation

Nykode Therapeutics
Regulatory press release20.08.2026 klo 16.22

NYKD: Nykode Therapeutics Receives New U.S. Patent Strengthening Intellectual Property Protection for its fully individualized VB10.NEO cancer vaccine program

Nykode Therapeutics
Regulatory press release06.08.2026 klo 21.05

Nykode Therapeutics - Grant of share options

Nykode Therapeutics
Regulatory press release04.08.2026 klo 23.15

Nykode Therapeutics - update on expected timeline for pending tax appeal

Nykode Therapeutics
Regulatory press release22.07.2026 klo 15.00

NYKD: Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO

Nykode Therapeutics
Regulatory press release27.05.2026 klo 08.00

Nykode Therapeutics - Quarterly Report Q1 2026

Nykode Therapeutics
Regulatory press release18.05.2026 klo 12.34

Nykode Therapeutics - Invitation to Q1 2026 Financial Results Presentation

Nykode Therapeutics
Regulatory press release13.05.2026 klo 12.15

Nykode Therapeutics ASA - Minutes of Annual General Meeting

Nykode Therapeutics
Regulatory press release07.05.2026 klo 14.54

NYKD: Nykode Therapeutics Doses First Patient in Abili-T Phase II Randomized Trial evaluating Abi-suva in HPV16-Positive, PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer Patients

Nykode Therapeutics
Regulatory press release30.04.2026 klo 09.30

NYKD: Nykode Therapeutics Presents AI-Powered Immunotherapy Design Capabilities at BioPharma Drug Discovery Nexus 2026

Nykode Therapeutics
Regulatory press release21.04.2026 klo 09.30

Nykode Therapeutics ASA - Notice of Annual General Meeting

Nykode Therapeutics
Regulatory press release20.04.2026 klo 13.00

NYKD: Nykode Therapeutics Presents Additional Immunogenicity Data from VB-C-03 Trial at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Nykode Therapeutics